评估打击劣药和假药的知识、态度和做法以及需求方干预措施:范围审查。

IF 2.5 Q1 HEALTH POLICY & SERVICES
Journal of Pharmaceutical Policy and Practice Pub Date : 2025-09-12 eCollection Date: 2025-01-01 DOI:10.1080/20523211.2025.2550369
Eishita Pal, Lubna Merchant, Alain K Koffi, Reema Mehta, Jean Christophe Rusatira, Lev Kubiak, Henry Joseph Michtalik, Patrick Caubel, Saifuddin Ahmed
{"title":"评估打击劣药和假药的知识、态度和做法以及需求方干预措施:范围审查。","authors":"Eishita Pal, Lubna Merchant, Alain K Koffi, Reema Mehta, Jean Christophe Rusatira, Lev Kubiak, Henry Joseph Michtalik, Patrick Caubel, Saifuddin Ahmed","doi":"10.1080/20523211.2025.2550369","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The proliferation of substandard and falsified medical products (SFM) poses a significant threat to public health globally. Despite rigorous surveillance and law enforcement efforts, risk of exposure to SFM is on the rise, notably through online pharmacies. The current interventions predominantly target the pharmaceutical supply chains through legal and regulatory frameworks, while there is a noticeable deficiency in focusing on interventions for healthcare providers and consumers. This scoping review aims to summarise the current literature on SFM, focusing on their health and economic consequences, and to assess the knowledge, attitudes, and practices of healthcare providers and the general public.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted across PubMed, Embase, and Scopus databases, focusing on studies from the past 15 years that provided estimates on mortality, morbidities and economic impacts of SFM and covered the following topic areas: knowledge, attitudes and practices of healthcare providers, patients and general public; and population level interventions regarding SFM. We exclude non-peer-reviewed literature.</p><p><strong>Results: </strong>A total of 78 studies met the inclusion criteria and were analyzed. These studies suggest that the data on adverse effects on health and economic impact of SF medicines are predominantly based on statistical models, and empirical data are grossly lacking. Knowledge of risks, identification of SFM, and reporting to regulatory authorities are substantially low among healthcare providers and general public.</p><p><strong>Discussion: </strong>This review highlights the need for innovative, targeted strategies - such as digital health interventions, enhanced training programs for healthcare providers, and context-specific public awareness campaigns - to bridge the gap between awareness and effective practice.</p><p><strong>Conclusions: </strong>Our study underscores that a multifaceted approach must not only reinforce regulatory frameworks and surveillance systems for protecting the supply chains but also proactively empower both health providers and consumers to identify and combat SFM in today's rapidly evolving digital landscape.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2550369"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12434857/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review.\",\"authors\":\"Eishita Pal, Lubna Merchant, Alain K Koffi, Reema Mehta, Jean Christophe Rusatira, Lev Kubiak, Henry Joseph Michtalik, Patrick Caubel, Saifuddin Ahmed\",\"doi\":\"10.1080/20523211.2025.2550369\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The proliferation of substandard and falsified medical products (SFM) poses a significant threat to public health globally. Despite rigorous surveillance and law enforcement efforts, risk of exposure to SFM is on the rise, notably through online pharmacies. The current interventions predominantly target the pharmaceutical supply chains through legal and regulatory frameworks, while there is a noticeable deficiency in focusing on interventions for healthcare providers and consumers. This scoping review aims to summarise the current literature on SFM, focusing on their health and economic consequences, and to assess the knowledge, attitudes, and practices of healthcare providers and the general public.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted across PubMed, Embase, and Scopus databases, focusing on studies from the past 15 years that provided estimates on mortality, morbidities and economic impacts of SFM and covered the following topic areas: knowledge, attitudes and practices of healthcare providers, patients and general public; and population level interventions regarding SFM. We exclude non-peer-reviewed literature.</p><p><strong>Results: </strong>A total of 78 studies met the inclusion criteria and were analyzed. These studies suggest that the data on adverse effects on health and economic impact of SF medicines are predominantly based on statistical models, and empirical data are grossly lacking. Knowledge of risks, identification of SFM, and reporting to regulatory authorities are substantially low among healthcare providers and general public.</p><p><strong>Discussion: </strong>This review highlights the need for innovative, targeted strategies - such as digital health interventions, enhanced training programs for healthcare providers, and context-specific public awareness campaigns - to bridge the gap between awareness and effective practice.</p><p><strong>Conclusions: </strong>Our study underscores that a multifaceted approach must not only reinforce regulatory frameworks and surveillance systems for protecting the supply chains but also proactively empower both health providers and consumers to identify and combat SFM in today's rapidly evolving digital landscape.</p>\",\"PeriodicalId\":16740,\"journal\":{\"name\":\"Journal of Pharmaceutical Policy and Practice\",\"volume\":\"18 1\",\"pages\":\"2550369\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12434857/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Policy and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/20523211.2025.2550369\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2025.2550369","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景:伪劣医疗产品(SFM)的泛滥对全球公共卫生构成重大威胁。尽管有严格的监督和执法努力,但接触SFM的风险正在上升,特别是通过在线药店。目前的干预措施主要通过法律和监管框架针对药品供应链,而在关注医疗保健提供者和消费者的干预措施方面存在明显不足。本综述旨在总结当前关于SFM的文献,重点关注其健康和经济后果,并评估卫生保健提供者和公众的知识、态度和做法。方法:在PubMed、Embase和Scopus数据库中进行了全面的文献检索,重点关注过去15年提供SFM死亡率、发病率和经济影响估计的研究,涵盖以下主题领域:卫生保健提供者、患者和公众的知识、态度和实践;以及人口层面的SFM干预措施。我们排除了未经同行评议的文献。结果:共有78项研究符合纳入标准并进行了分析。这些研究表明,关于顺丰药物对健康和经济的不良影响的数据主要基于统计模型,经验数据严重缺乏。医疗保健提供者和普通公众对风险、SFM识别和向监管机构报告的了解程度非常低。讨论:本综述强调需要创新的、有针对性的战略,如数字卫生干预、加强卫生保健提供者培训计划和针对具体情况的公共宣传活动,以弥合意识和有效实践之间的差距。结论:我们的研究强调,多方面的方法不仅必须加强保护供应链的监管框架和监督系统,而且还必须主动赋予卫生服务提供者和消费者在当今快速发展的数字环境中识别和打击SFM的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review.

Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review.

Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review.

Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review.

Background: The proliferation of substandard and falsified medical products (SFM) poses a significant threat to public health globally. Despite rigorous surveillance and law enforcement efforts, risk of exposure to SFM is on the rise, notably through online pharmacies. The current interventions predominantly target the pharmaceutical supply chains through legal and regulatory frameworks, while there is a noticeable deficiency in focusing on interventions for healthcare providers and consumers. This scoping review aims to summarise the current literature on SFM, focusing on their health and economic consequences, and to assess the knowledge, attitudes, and practices of healthcare providers and the general public.

Methods: A comprehensive literature search was conducted across PubMed, Embase, and Scopus databases, focusing on studies from the past 15 years that provided estimates on mortality, morbidities and economic impacts of SFM and covered the following topic areas: knowledge, attitudes and practices of healthcare providers, patients and general public; and population level interventions regarding SFM. We exclude non-peer-reviewed literature.

Results: A total of 78 studies met the inclusion criteria and were analyzed. These studies suggest that the data on adverse effects on health and economic impact of SF medicines are predominantly based on statistical models, and empirical data are grossly lacking. Knowledge of risks, identification of SFM, and reporting to regulatory authorities are substantially low among healthcare providers and general public.

Discussion: This review highlights the need for innovative, targeted strategies - such as digital health interventions, enhanced training programs for healthcare providers, and context-specific public awareness campaigns - to bridge the gap between awareness and effective practice.

Conclusions: Our study underscores that a multifaceted approach must not only reinforce regulatory frameworks and surveillance systems for protecting the supply chains but also proactively empower both health providers and consumers to identify and combat SFM in today's rapidly evolving digital landscape.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice Health Professions-Pharmacy
CiteScore
4.70
自引率
9.50%
发文量
81
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信